Discover
INBX
Inhibrx Biosciences, Inc.
109.35
2 x 78.34
2 x 136.39
bid
ask
+
4.62
4.41%
2 @ 04:00 PM
109.35 +0.00 (0.00%)
| Ytd | 38.42% | |
| 1y | 310.32% |
105.04
day range
110.39
26.20
52 week range
155.29
| Open | 106.18 | Prev Close | 104.73 | Low | 105.04 | High | 110.39 | Mkt Cap | 1.61B |
| Vol | 483.38K | Avg Vol | 316.06K | EPS | -8.88 | P/E | N/A | Forward P/E | -12.48 |
| Beta | 3.67 | Short Ratio | 12.24 | Inst. Own | 91.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-13 | 50-d Avg | 99.26 | 200-d Avg | 90.18 | 1yr Est | 266.67 |
| Income Statement | |||
| Operating Expenses | 32.15M | ||
| Research and Development Expense | 23.90M | ||
| Selling, General and Administrative Expense | 8.25M | ||
| Operating Income | -32.15M | ||
| Interest Expense | 5.69M | ||
| Income Tax Expense | 3.00K | ||
| Net Income | -36.65M | ||
| Net Income Common Stock | -36.65M | ||
| Net Income Common Stock (USD) | -36.65M | ||
| Consolidated Income | -36.65M | ||
| Earnings per Basic Share | -2.34 | ||
| Earnings per Basic Share (USD) | -2.34 | ||
| Earnings per Diluted Share | -2.34 | ||
| Earning Before Interest & Taxes (EBIT) | -30.95M | ||
| Earning Before Interest & Taxes (USD) | -30.95M | ||
| Weighted Average Shares | 15.67M | ||
| Weighted Average Shares Diluted | 15.67M | ||
| Balance Sheet | |||
| Cash and Equivalents | 133.34M | ||
| Cash and Equivalents (USD) | 133.34M | ||
| Trade and Non-Trade Receivables | 132.00K | ||
| Current Assets | 142.21M | ||
| Property, Plant & Equipment Net | 7.24M | ||
| Total Assets | 154.22M | ||
| Debt Current | 2.49M | ||
| Total Debt | 181.63M | ||
| Current Liabilities | 28.06M | ||
| Debt Non-Current | 179.14M | ||
| Total Liabilities | 207.20M | ||
| Accumulated Retained Earnings (Deficit) | -316.28M | ||
| Shareholders Equity | -52.98M | ||
| Shareholders Equity (USD) | -52.98M | ||
| Assets Non-Current | 12.01M | ||
| Total Debt (USD) | 181.63M | ||
| Liabilities Non-Current | 179.14M | ||
| Trade and Non-Trade Payables | 9.80M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.02M | ||
| Net Cash Flow from Financing | 1.60M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -28.31M | ||
| Issuance (Purchase) of Equity Shares | 1.60M | ||
| Net Cash Flow from Operations | -29.92M | ||
| Share Based Compensation | 3.10M | ||